Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.  Peloton Therapeutics’ lead program, PT2977, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of renal and other cancers.

Peloton Therapeutics, Inc. was acquired by Merck in May 2019.